论文部分内容阅读
目的：探讨急性出血坏死性胰腺炎（ＡＨＮＰ）早期细菌易位规律及生长抑素（ｓｔｉｌａｍｉｎ）与头孢噻甲羧肟（Ｃｅｆｔａｚｉｄｉｍｅ）对其的影响。方法：应用去氧胆酸钠逆行胰管注射致大鼠ＡＨＮＰ模型。一、将ＳＤ大鼠随机分为模型组和对照组，１２及２４小时后采样。二、将ＳＤ大鼠模型随机分为：生理盐水治疗组，Ｓｔｉｌａｍｉｎ治疗组，Ｃｅｆｔａｚｉｄｉｍｅ治疗组，对照组同上。各组经腹腔用药，２４小时后采样，观察各组胰肝细菌学指标、小肠粘膜改变、肠组织ＭＤＡ含量及胰腺光镜病理学评分。结果：一、模型组胰肝细菌检出率及菌落计数明显高于假手术组（Ｐ＜００５），检出菌以大肠杆菌和肠球菌为主，肠粘膜病变主要在回肠。二、肝胰菌落计数（ＣＦＵ／ｇ）：生长抑素组和抗生素组明显低于盐水组，（Ｐ＜００５）。抗生素组检出的细菌以肠球菌为主。生长抑素组肠粘膜病变较其它组明显减轻，且肠组织ＭＤＡ含量明显减少（Ｐ＜００１），除出血外（Ｐ＜００５）胰腺病理评分较其它组未见显著差异。结论：ＡＨＮＰ早期应用抗生素和生长抑素能减轻细菌的肠道透壁易位，但不能阻止耐药菌易位。生长抑素腹腔用药能保护肠粘膜屏障。其机理与减轻氧自由基对肠道损伤有关
Objective: To investigate the early bacterial translocation and the effect of stilamin and ceftazidime on acute hemorrhagic necrotizing pancreatitis (AHNP). Methods: The rat model of AHNP was induced by sodium desoxycholate injection. First, the SD rats were randomly divided into model group and control group, 12 and 24 hours after sampling. Second, the SD rat model was randomly divided into: saline treatment group, Stilamin treatment group, Ceftazidime treatment group, the control group above. The rats in each group were administered intraperitoneally and sampled 24 hours later. Bacteriological indicators of pancreas, intestinal mucosal changes, intestinal mucosal MDA content and pancreatic pathological score were observed. Results: First, the detection rate and the colony count of the pancreas in the model group were significantly higher than those in the sham operation group (P <005). Escherichia coli and enterococci were the main pathogens in the model group, while the intestinal mucosal lesions were mainly in the ileum. Second, the number of hepatopancreas colonies (CFU / g): somatostatin group and antibiotic group was significantly lower than saline group (P <0 05). Antibiotic group of bacteria to enterococci-based. Somatostatin group mucosal lesion was significantly reduced compared with other groups, and the MDA content of intestinal tissue was significantly reduced (P <001), except for hemorrhage (P <005), pancreatic pathological score than the other groups showed no significant difference. Conclusion: The early application of AHNP antibiotics and somatostatin can reduce bacterial intestinal transmutation translocation, but can not prevent the translocation of resistant bacteria. Somatostatin intraperitoneal drug can protect the intestinal mucosal barrier. The mechanism of reducing oxygen free radicals on the intestinal damage